Lumida
/KE
⌘K
Kimball Electronics Inc

Kimball Electronics Inc

KE
$23.97USD-1.76%-0.43 today

MARKET CAP

576.5M

P/E (TTM)

16.6x

FWD P/E

16.7x

DAY RANGE

$23 – $24

52W RANGE

$18
$33

AI Summary

Stalk
TrimMedium

KE is in a Stage 3 distribution phase despite a long-term uptrend, with price clustering under declining EMAs and failed highs signaling medium-term bearish bias. Short-term price action oscillates around the 9/21 EMA and 50 DMA without clear momentum or exhaustion, offering no urgency to scale into new positions. Execution should focus on trimming into overhead supply near the short-term EMA cluster and 50 DMA. A decisive reclaim and sustained trade above these levels with follow-through would invalidate the bearish medium-term stance.

  • Medical net sales up 10% YoY in Q3, diversifying revenue base.
  • Q3 cash from operations of $14.9M marks nine straight positive quarters.
  • Automotive segment net sales dropped 12% YoY, weighing on overall revenue.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Kimball Electronics (NASDAQ: KE) is a prominent contract manufacturer specializing in the medical, automotive, and industrial sectors. The company has a strong competitive edge in the medical contract manufacturing organization (CMO) space, emphasizing tailored, high-reliability manufacturing solutions. Its position in the growing medical sector allows for leveraging core competencies amid broader structural shifts in various industries, particularly as demand for medical devices continues to increase.

Bull says

  • Medical net sales up 10% YoY in Q3, diversifying revenue base.
  • Q3 cash from operations of $14.9M marks nine straight positive quarters.
  • New 300k sqft Indianapolis facility to ramp by EOY 2026 on high-margin CMO.
  • Q3 buybacks of $4M executed; debt reduced by 40% year-to-date.
  • FY26 adjusted operating margin expected at the high end of guidance.
  • High earnings yield, strong book-to-price, and positive momentum factors suggest upside.

Bear says

  • Automotive segment net sales dropped 12% YoY, weighing on overall revenue.
  • New Indianapolis facility start-up may pressure gross margin by 40–50bps in FY27.
  • Analyst earnings revisions are significantly negative, signaling potential EPS cuts.
  • Short interest is elevated, reflecting investor skepticism and downside risk.
  • Profitability factors are weak and medical client concentration heightens revenue risk.
  • Tariff uncertainty may raise costs and strain non-medical segments.

Earnings Call · Q3 2025 · Mgmt. Guidance

Updated 05-30-2026neutral

Transcript signals

Bull points

  • We have ample liquidity to weather the short-term unpredictable environment and significant dry powder to opportunistically invest in the business longer term.
  • As part of today's release, we are reiterating our guidance for fiscal 2025 with the expectation that we'll be at the top end of the range for sales and operating income.
  • The step of adding a new, larger, medically focused manufacturing facility in Indianapolis reflects our commitment to the CMO.

Bear points

  • net sales totaled $375 million, a 10% decline year over year when excluding the AT&M business, which was divested earlier this fiscal year.
  • Our automotive business is heavily concentrated in North America and China, but growing in Europe with the launch of the breaking platform in Romania. For the third consecutive quarter, results in China were strong. Sales in Europe increased modestly as the new electronic braking program in Romania started to ramp production. North America, on the other hand, reported a decline in sales, primarily driven by the electronic braking program in Renosa, as previously discussed.
  • The decrease occurred in all regions with the largest decline in Europe, followed by Asia, and a modest decrease in North America. Our customers continue to experience market share loss from the commoditization of smart meters and reductions in climate control and public safety products.
Read full transcript analysis ›